BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
-18.21%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$12.2B
AUM Growth
+$12.2B
(-20%)
Cap. Flow
-$49.6M
Cap. Flow
% of AUM
-0.41%
Top 10 Holdings %
Top 10 Hldgs %
86.1%
Holding
101
New
4
Increased
12
Reduced
21
Closed
10
Top Buys
| 1 |
Acadia Pharmaceuticals
ACAD
|
$182M |
| 2 |
AMRN
Amarin Corp
AMRN
|
$116M |
| 3 |
Kodiak Sciences
KOD
|
$64.9M |
| 4 |
CMTA
Clementia Pharmaceuticals Inc.
CMTA
|
$21.1M |
| 5 |
Krystal Biotech
KRYS
|
$13.9M |
Top Sells
| 1 |
GHDX
Genomic Health, Inc.
GHDX
|
$132M |
| 2 |
SAGE
Sage Therapeutics
SAGE
|
$80.2M |
| 3 |
NVTA
Invitae Corporation
NVTA
|
$49.7M |
| 4 |
ECYT
Endocyte, Inc. Common Stock
ECYT
|
$45.3M |
| 5 |
Galapagos
GLPG
|
$19.5M |
Sector Composition
| 1 | Healthcare | 92.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CBAY
26
DELISTED
Cymabay Therapeutics
CBAY
| $38.7M | 0.32% |
4,917,700
| – | – |
|
|
TCDA
27
DELISTED
Tricida, Inc. Common Stock
TCDA
| $37.7M | 0.31% |
1,600,000
| – | – |
|
|
DBVT
28
DBV Technologies
DBVT
$249M
| $35.4M | 0.29% |
5,509,560
| – | – |
|
29
Zymeworks
ZYME
$1.07B
| $25.1M | 0.21% |
1,708,472
+397,387
| +30% | +$5.83M |
|
30
Insmed
INSM
$30.3B
| $24.3M | 0.2% |
1,851,982
| – | – |
|
31
Neurogene
NGNE
$284M
| $23.6M | 0.19% |
10,934,154
| – | – |
|
|
BOLD
32
DELISTED
Audentes Therapeutics, Inc
BOLD
| $19.4M | 0.16% |
910,463
+517,241
| +132% | +$11M |
|
33
uniQure
QURE
$954M
| $17.4M | 0.14% |
605,000
| – | – |
|
|
34
Krystal Biotech
KRYS
$4.35B
| $16.3M | 0.13% |
784,674
+670,000
| +584% | +$13.9M |
|
35
Merus
MRUS
$5.04B
| $16.2M | 0.13% |
1,160,014
| – | – |
|
|
AIMT
36
DELISTED
Aimmune Therapeutics, Inc.
AIMT
| $16.1M | 0.13% |
673,908
| – | – |
|
37
Xencor
XNCR
$594M
| $15.9M | 0.13% |
440,186
-162,309
| -27% | -$5.87M |
|
38
Solid Biosciences
SLDB
$448M
| $15.8M | 0.13% |
587,884
| – | – |
|
|
MYOK
39
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $15.4M | 0.13% |
315,243
-41,972
| -12% | -$2.05M |
|
40
Abeona Therapeutics
ABEO
$356M
| $15M | 0.12% |
2,103,164
-81,200
| -4% | -$580K |
|
|
RARX
41
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $15M | 0.12% |
823,113
+645,161
| +363% | +$11.7M |
|
|
ACGN
42
DELISTED
Aceragen, Inc. Common Stock
ACGN
| $13.4M | 0.11% |
4,836,237
+2,340
| +0% | +$6.49K |
|
43
Spyre Therapeutics
SYRE
$1.02B
| $12.8M | 0.11% |
1,713,604
+325,732
| +23% | +$2.44M |
|
44
Sangamo Therapeutics
SGMO
$161M
| $11.5M | 0.09% |
999,823
-284,100
| -22% | -$3.26M |
|
|
CFRX
45
DELISTED
ContraFect Corporation
CFRX
| $10.9M | 0.09% |
7,153,076
| – | – |
|
46
Novavax
NVAX
$1.2B
| $8.68M | 0.07% |
4,718,318
| – | – |
|
47
Marker Therapeutics
MRKR
$11.2M
| $8.33M | 0.07% |
+1,500,000
| New | +$8.33M |
|
|
BLCM
48
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $7.82M | 0.06% |
2,677,818
| – | – |
|
49
AnaptysBio
ANAB
$630M
| $7.21M | 0.06% |
113,086
| – | – |
|
50
InflaRx
IFRX
$117M
| $6.51M | 0.05% |
178,987
| – | – |
|